Patients
Between September 1, 2021, and March 23, 2022, 37 patients with R/R MM were screened and 33 were enrolled. All 33 enrolled patients received anti-GPRC5D CAR T cells and were evaluated for activity and safety (Fig Flow diagram. BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; GPRC5D, G protein–coupled receptor, class C group 5 member D.Patient Baseline Characteristics